204 related articles for article (PubMed ID: 33592546)
1. The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy.
Asadzadeh Z; Mansoori B; Mohammadi A; Kazemi T; Mokhtarzadeh A; Shanehbandi D; Hemmat N; Derakhshani A; Brunetti O; Safaei S; Aghajani M; Najafi S; Silvestris N; Baradaran B
Biomed Pharmacother; 2021 May; 137():111364. PubMed ID: 33592546
[TBL] [Abstract][Full Text] [Related]
2. Effects of CD133 Silencing on Survival and Migration of HT-29 Colorectal Cancer Cells.
Akbari M; Shanehbandi D; Asadi M; Shomali N; Faraji A; Khaze V; Pakdel A; Mokhtarzadeh A; Ebrahimi AA; Shabani A; Bardaran B
Iran J Immunol; 2019 Sep; 16(3):246-257. PubMed ID: 31552833
[TBL] [Abstract][Full Text] [Related]
3. siRNA-mediated silencing of Nanog reduces stemness properties and increases the sensitivity of HepG2 cells to cisplatin.
Alemohammad H; Motafakkerazad R; Asadzadeh Z; Farsad N; Hemmat N; Najafzadeh B; Vasefifar P; Baradaran B
Gene; 2022 May; 821():146333. PubMed ID: 35182674
[TBL] [Abstract][Full Text] [Related]
4. CD133 suppression increases the sensitivity of prostate cancer cells to paclitaxel.
Aghajani M; Mokhtarzadeh A; Aghebati-Maleki L; Mansoori B; Mohammadi A; Safaei S; Asadzadeh Z; Hajiasgharzadeh K; Khaze Shahgoli V; Baradaran B
Mol Biol Rep; 2020 May; 47(5):3691-3703. PubMed ID: 32246247
[TBL] [Abstract][Full Text] [Related]
5. Suppression of colorectal cancer metastasis by nigericin through inhibition of epithelial-mesenchymal transition.
Zhou HM; Dong TT; Wang LL; Feng B; Zhao HC; Fan XK; Zheng MH
World J Gastroenterol; 2012 Jun; 18(21):2640-8. PubMed ID: 22690072
[TBL] [Abstract][Full Text] [Related]
6. The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer.
Elsaba TM; Martinez-Pomares L; Robins AR; Crook S; Seth R; Jackson D; McCart A; Silver AR; Tomlinson IP; Ilyas M
PLoS One; 2010 May; 5(5):e10714. PubMed ID: 20502714
[TBL] [Abstract][Full Text] [Related]
7. Knocking down LSD1 inhibits the stemness features of colorectal cancer stem cells.
Chen J; Zhao J; Ding J; Wang Z; Du J; Wu C
Braz J Med Biol Res; 2020; 53(7):e9230. PubMed ID: 32520208
[TBL] [Abstract][Full Text] [Related]
8. TWIST1 Promotes Colorectal Carcinoma Stemness and Oxaliplatin Resistance by Activating Microfibrillar-Associated Protein 2.
Liu Y; Chen M; Wu B
Assay Drug Dev Technol; 2023 Jul; 21(5):202-211. PubMed ID: 37428562
[TBL] [Abstract][Full Text] [Related]
9. Salinomycin selectively targets 'CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines.
Dong TT; Zhou HM; Wang LL; Feng B; Lv B; Zheng MH
Ann Surg Oncol; 2011 Jun; 18(6):1797-804. PubMed ID: 21267784
[TBL] [Abstract][Full Text] [Related]
10. Colorectal cancer stem cell-derived exosomal long intergenic noncoding RNA 01315 (LINC01315) promotes proliferation, migration, and stemness of colorectal cancer cells.
Li Y; Wu M; Xu S; Huang H; Yan L; Gu Y
Bioengineered; 2022 Apr; 13(4):10827-10842. PubMed ID: 35470736
[TBL] [Abstract][Full Text] [Related]
11. CD133: An emerging prognostic factor and therapeutic target in colorectal cancer.
Akbari M; Shomali N; Faraji A; Shanehbandi D; Asadi M; Mokhtarzadeh A; Shabani A; Baradaran B
Cell Biol Int; 2020 Feb; 44(2):368-380. PubMed ID: 31579983
[TBL] [Abstract][Full Text] [Related]
12. Suppression of Nanog inhibited cell migration and increased the sensitivity of colorectal cancer cells to 5-fluorouracil.
Khosravi N; Shahgoli VK; Amini M; Safaei S; Mokhtarzadeh A; Mansoori B; Derakhshani A; Baghbanzadeh A; Baradaran B
Eur J Pharmacol; 2021 Mar; 894():173871. PubMed ID: 33460610
[TBL] [Abstract][Full Text] [Related]
13. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
[TBL] [Abstract][Full Text] [Related]
14. Bufalin reverses multidrug resistance by regulating stemness through the CD133/nuclear factor-κB/MDR1 pathway in colorectal cancer.
Zhan Y; Qiu Y; Wang H; Wang Z; Xu J; Fan G; Xu J; Li W; Cao Y; Le VM; Ly HT; Yuan Z; Xu K; Yin P
Cancer Sci; 2020 May; 111(5):1619-1630. PubMed ID: 32058643
[TBL] [Abstract][Full Text] [Related]
15. ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
Ma L; Liu T; Jin Y; Wei J; Yang Y; Zhang H
Tumour Biol; 2016 Sep; 37(9):12889-12896. PubMed ID: 27449042
[TBL] [Abstract][Full Text] [Related]
16. Exosomes from CD133
Zhao H; Chen S; Fu Q
J Cell Biochem; 2020 Jun; 121(5-6):3286-3297. PubMed ID: 31960989
[TBL] [Abstract][Full Text] [Related]
17. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
[TBL] [Abstract][Full Text] [Related]
18. Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA.
Gu WJ; Liu HL
Anticancer Drugs; 2013 Jul; 24(6):566-76. PubMed ID: 23525071
[TBL] [Abstract][Full Text] [Related]
19. In vitro characterization of CD133
Nair RM; Balla MM; Khan I; Kalathur RKR; Kondaiah P; Vemuganti GK
BMC Cancer; 2017 Nov; 17(1):779. PubMed ID: 29162051
[TBL] [Abstract][Full Text] [Related]
20. Effect of Bmi-1-mediated NF-κB signaling pathway on the stem-like properties of CD133+ human liver cancer cells.
Ma DQ; Zhang YH; Ding DP; Li J; Chen LL; Tian YY; Ao KJ
Cancer Biomark; 2018; 22(3):575-585. PubMed ID: 29843222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
